Kiniksa Pharmaceuticals (KNSA) financial statements
Kiniksa Pharmaceuticals reported revenue of $678M in fiscal 2025, up 104.8% a year over 4 years.
Net income was $59M.
Free cash flow was $136M.
The diluted share count rose 4264% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Kiniksa Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $39M | $220M | $270M | $423M | $678M |
| Cost of revenue | — | — | — | — | $9M | $23M | $33M | $61M | $78M |
| Gross profit | — | — | — | — | $29M | $197M | $237M | $362M | $600M |
| Research and development | $56M | $87M | $135M | $112M | $99M | $65M | $76M | $112M | $97M |
| Selling, general and admin | $9M | $22M | $35M | $45M | $86M | $98M | $129M | $168M | $196M |
| Operating income | -$65M | -$108M | -$170M | -$157M | -$157M | $10M | -$25M | -$46M | $77M |
| Pre-tax income | -$65M | -$103M | -$164M | -$156M | -$157M | $11M | -$17M | -$36M | $89M |
| Income tax | $2,000 | -$214,000 | -$2M | $5M | $1M | -$172M | -$31M | $7M | $30M |
| Net income | -$65M | -$103M | -$162M | -$161M | -$158M | $183M | $14M | -$43M | $59M |
| EPS (diluted) | -$35.85 | -$3.49 | -$2.99 | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Diluted shares | 2M | 30M | 54M | 62M | 69M | 70M | 72M | 71M | 79M |
| Gross margin | — | — | — | — | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | — | — | — | — | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Net margin | — | — | — | — | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
Balance sheet
Fiscal years, from Kiniksa Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $46M | $307M | $233M | $323M | $182M | $191M | $206M | $244M | $414M |
| Receivables | — | — | — | — | $4M | $13M | $21M | $42M | $16M |
| Inventory | — | — | — | $0 | $4M | $22M | $31M | $26M | $55M |
| Total current assets | $47M | $314M | $242M | $333M | $196M | $243M | $276M | $332M | $527M |
| Property, plant and equipment | $125,000 | $6M | $6M | $4M | $3M | $2M | $734,000 | $662,000 | $2M |
| Total assets | $47M | $322M | $255M | $349M | $233M | $460M | $526M | $581M | $764M |
| Total current liabilities | $17M | $43M | $28M | $32M | $45M | $47M | $64M | $101M | $139M |
| Total liabilities | $17M | $43M | $29M | $38M | $48M | $64M | $87M | $142M | $196M |
| Shareholders' equity | -$90M | $279M | $225M | $312M | $185M | $396M | $439M | $438M | $568M |
| Net debt | -$46M | -$72M | -$47M | -$114M | -$122M | -$123M | -$108M | -$184M | -$166M |
Cash flow
Fiscal years, from Kiniksa Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50M | -$81M | -$158M | -$137M | -$126M | $6M | $13M | $26M | $138M |
| Capital spending | $69,000 | $5M | $3M | $283,000 | $415,000 | $105,000 | $130,000 | $277,000 | $2M |
| Free cash flow | -$50M | -$86M | -$162M | -$137M | -$127M | $6M | $13M | $25M | $136M |
| Stock-based compensation | $897,000 | $6M | $15M | $21M | $25M | $25M | $27M | $31M | $37M |
| Dividends paid | $0 | $0 | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | -328.7% | 2.6% | 4.9% | 6.0% | 20.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KNSA.
Open KNSA in InvestinglyQuestions
What was Kiniksa Pharmaceuticals's revenue in 2025?
$678M in fiscal 2025, from its 10-K filing.
How much free cash flow does Kiniksa Pharmaceuticals generate?
$136M in fiscal 2025 (operating cash flow minus capital spending).
From Kiniksa Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.